Shares of Hims & Hers Health Inc. (HIMS) plummeted 25.76% in the pre-market trading session on Friday, after the U.S. Food and Drug Administration announced that the shortage of Novo Nordisk's popular weight-loss and diabetes drugs Ozempic and Wegovy has been resolved.
The resolution of the shortage could potentially restrict how telehealth programs like Hims & Hers offer cheaper versions known as compounded drugs, which have seen a boom in demand due to the tight supply of Novo Nordisk's treatments. Regulations allow compounding pharmacies to copy brand-name medicines only when they are in short supply.
With the shortage ending, companies offering compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, could face challenges. This development poses a threat to Hims & Hers, which offers compounded semaglutide as an alternative to the brand-name drugs.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。